Relacorilant

Relacorilant

Relacorilant

Chemical compound

Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome.[1] It is also under development for the treatment of solid tumors and alcoholism.[1][2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.[1]

Quick Facts Clinical data, Other names ...

References

  1. [1]
    "Relacorilant - Corcept Therapeutics - AdisInsight".
  2. [2]
    Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF (2017). "High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer". Gynecol. Oncol. 146 (1): 153–160. doi:10.1016/j.ygyno.2017.04.012. PMC 5955699. PMID 28456378.



Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Relacorilant, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.